1. Hennessey JV (2003) Levothyroxine a new drug? Since when? How could that be? Thyroid 13: 279–282
2. US Department of Health and Human Services, FDA, and Center for Drug Evaluation and Research (2002) Guidance for industry: bioavailability and bioequivalence studies for orally administered drug products—general considerations [
http://www.fda.gov/cder/guidance/4964dft.pdf
] (accessed 19 July 2006)
3. FDA (2005) Itinery for the joint public meeting on equivalence of levothyroxine sodium products [
http://www.fda.gov/ohrms/dockets/dockets/05n0137/05n-0137-lst0001.pdf
] (accessed 19 July 2006)
4. FDA (2005) Code of federal regulations, title 21, vol 5, subchapter D, part 320 [
http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=320&show
] (accessed 19 July 2006)
5. Carr D et al. (1988) Fine adjustment of thyroxine replacement dosage: comparison of the thyrotropin releasing hormone test using a sensitive thyrotropin assay with measurement of free thyroid hormones and clinical assessment. Clin Endocrinol 28: 325–333